Navigation Links
Alnylam in Medical News

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study

MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced today at the 18th Annual Drug Delivery to the Lungs meeting held in Edi...

Isis to Receive $4.6 Million From Alnylam

CARLSBAD, Calif., May 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as its portion of the upfront fees in the recently announced transaction between Takeda P...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference

...axis of delayed graft function after kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling precl...

aTyr Pharma Raises an Additional $12 Million

...ng and leading many successful biotechnology companies, including Alkermes, alnylam Pharmaceuticals, Cubist Pharmaceuticals, Momenta Pharmaceuticals and Sirtri...ealth Services, Advanced Inhalation Research, Akamai Technologies, Allaire, alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Sys...

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

I-Therapeutix, Inc. Closes $15 Million Financing

...companies. Polaris-backed successes in life sciences include Adnexus (sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Pharmaceuticals (MNTA), and Transform Pharmaceuticals (sold to Johnson & Johnson). Curren...

Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

...ed by Quark through the gene discovery platform BiFAR(TM). For the structure of these products, Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in IND-enabling nonclinical studies a...

Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...
Alnylam in Medical Technology

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study

MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients. ALN-RSV01 is a RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... Isis received a $375,000 milestone payment from alnylam for initiation of clinical trials on ALN-VSP. ... Isis earned milestone payments from Archemix and alnylam because each company advanced drugs that incorpora...e-stranded RNA interference (ssRNAi) technology to alnylam as part of a new strategic initiative to continue ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals Presents at Asia TIDES Conference

...ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling precli...

Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

...rom acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study. About Quark Pharmaceuticals, Inc. Quark ...

Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema

...mmencement of the trial triggers a milestone payment to Quark from Pfizer, a small percentage of which is payable by Quark to Silence Therapeutics and alnylam as technology license milestone payments. The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-45236...

Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss

...llular integrity. The AHLi-11 active molecule was designed and patented by Quark. The Company has licenses for certain RNAi intellectual property from alnylam and Silence Therapeutics About Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on disc...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

...oday publication of a study in the journal Cell by alnylam and Stanford University scientists on the role of ...ntigen recognition is poorly understood. Recently, alnylam scientists and collaborators have discovered a new...es, including cancer and viral infections. About alnylam ...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

...Officer. He further added that Calando has filed for patent protection on several siRNA duplexes against the RRM2 target and has licensed patents from alnylam Pharmaceuticals to enable it to develop and commercialize an RNAi therapeutic against this target. Further information about Calando can be found at...
Alnylam in Biological News

Mechanism for the in-vivo transport of siRNA

...ying mechanisms remained obscure. Markus Stoffel, ETH Zurich Professor at the Institute for Molecular Systems Biology, together with chemists from the alnylam Company, has now succeeded in elucidating the mechanism for the uptake of siRNA in combination with fatty acids in mammals. The corresponding paper, w...
Alnylam in Biological Technology

Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call

CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: New findings published in the journal Nature on the role of a microRNA, known as miR-21, in heart failure When: Monday, December 1, 2...

Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer

...r of companies achieve outstanding success. Among them are: Accordant Health Services, Acusphere, Advanced Inhalation Research (acquired by Alkermes), alnylam Pharmaceuticals, Aspect Medical Systems, Cubist Pharmaceuticals, deCODE genetics, GlycoFi (acquired by Merck), Momenta Pharmaceuticals and TransForm P...

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

...ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclin...

Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University

... Biotechonomy, Nobel Laureate Phil Sharp of MIT , Microsoft Startup Labs Managing Director Reed Sturtevant, Boston Power CEO Christina Lampe-Onnerud, alnylam Pharmaceuticals CEO John Maraganore, Boston Scientific Co-founder John Abele, and Yet-Ming Chiang, co-founder of A123Systems. Start-ups represent...

Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

...eutics); Christina Gamba-Vitalo, Senior Director Preclinical Development at alnylam Pharmaceuticals (topic: Progress in developing siRNAs as drugs); and Patric...ure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary struct...

Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day

... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...

The IN VIVO Blog Selects First Annual 'Deal of the Year'

... medical device industries, have selected a Deal of the Year for 2008 -- alnylam Pharmaceuticals' RNA interference alliance with Takeda Pharmaceuticals . ... example of how it pulls off this impressive feat." "The deal allows alnylam to end the year with approximately $500 million in cash and sets the RNAi p...

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

...development of microRNA-based therapeutics for hepatocellular carcinoma has been transferred to Regulus Therapeutics. Regulus, a joint venture between alnylam Pharmaceuticals and Isis Pharmaceuticals focused on the development of microRNA-based therapeutics, and Rosetta Genomics will continue collaborating u...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

...bsidiaries including: -- $2.0 million milestone payment from Bristol-Myers Squibb for a PCSK9 development candidate -- $4.6 million from alnylam Pharmaceuticals, Inc. -- $1.4 million from Antisense Therapeutics Limited -- $3.3 million from Ibis representing a 72% increase from second half o...
Other Tags
(Date:7/11/2014)... research conducted at Aarhus University has revealed that people ... are only half as likely as their urban counterparts ... colitis and Crohn,s disease. The study findings have recently ... . , "It is extremely exciting that we can ... more classic inflammatory diseases appear to depend on the ...
(Date:7/11/2014)... July 11, 2014 As reported by ... For Cocaine: Are Genetics To Blame (6/30), Indino Downey ... cocaine and paraphernalia to smoke it with. His father, ... that his son inherited from him may have something ... made the news during the 1980s and 1990s for ...
(Date:7/11/2014)... Leeds, England (PRWEB) July 11, 2014 Having ... later as a member of mental hospital staff, Roger Grainger ... among medical professionals in his new book, “You Never Get ... 4 people in the United Kingdom will experience some kind ... , “Society still needs to take a look at ...
(Date:7/11/2014)... 11, 2014 AngelWeddingDress is now providing ... 2014 summer collections ”. When it comes to buying ... comes AngelWeddingDress with the unlimited stock of beautiful wedding ... for its wonderful summer wedding gowns. , The ... clients to keep pace with the newest fashion trends. ...
(Date:7/11/2014)... Seattle, WA (PRWEB) July 11, 2014 ... but the rate of return to play has not ... at the American Orthopaedic Society for Sports Medicine’s ( ... for NFL players is approximately 90 percent no matter ... study highlighted the success rate of return to play ...
Breaking Medicine News(10 mins):Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
Other Contents